Difference between revisions of "Melanoma, KIT-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
(11 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | {{#lst: | + | {{#lst:Editorial board transclusions|mel}} |
<big>'''Note: these are regimens tested in biomarker-specific populations, please see the [[Melanoma|main melanoma page]] for other regimens.'''</big> | <big>'''Note: these are regimens tested in biomarker-specific populations, please see the [[Melanoma|main melanoma page]] for other regimens.'''</big> | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
+ | =Guidelines= | ||
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
+ | ==NCCN== | ||
+ | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492 NCCN Guidelines - Melanoma: Cutaneous].'' | ||
=Advanced or metastatic disease, TKI-naive= | =Advanced or metastatic disease, TKI-naive= | ||
==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}== | ==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}== | ||
Line 25: | Line 29: | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: upon progression, the dose of imatinib was escalated; see below.'' | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
Line 33: | Line 38: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[Imatinib (Gleevec)]] | + | *[[Imatinib (Gleevec)]] 400 mg PO once per day |
− | + | '''Continued indefinitely (see note)''' | |
− | |||
− | '''Continued indefinitely''' | ||
</div></div><br> | </div></div><br> | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 62: | Line 65: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''MSKCC 07-014:''' Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. [https://doi.org/10.1001/jama.2011.746 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21642685 PubMed] NCT00470470 | + | #'''MSKCC 07-014:''' Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. [https://doi.org/10.1001/jama.2011.746 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21642685/ PubMed] [https://clinicaltrials.gov/study/NCT00470470 NCT00470470] |
− | #'''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [https://doi.org/10.1200/jco.2012.47.7836 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23775962/ PubMed] NCT00424515 | + | |
+ | =Advanced or metastatic disease, TKI-exposed= | ||
+ | ==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ Hodi et al. 2013 (BUS255)] | ||
+ | |2006-2011 | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *Gene: KIT | ||
+ | *Alteration: amplification and mutation | ||
+ | *Acceptable methods of measurement: PCR or HPLC | ||
+ | ====Prior treatment criteria==== | ||
+ | *[[#Imatinib_monotherapy|Imatinib]] 400 mg/day, with progression | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Targeted therapy==== | ||
+ | *[[Imatinib (Gleevec)]] 400 mg PO twice per day | ||
+ | '''Continued indefinitely''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [https://doi.org/10.1200/jco.2012.47.7836 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23775962/ PubMed] [https://clinicaltrials.gov/study/NCT00424515 NCT00424515] | ||
+ | |||
[[Category:Melanoma regimens]] | [[Category:Melanoma regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Skin cancers]] | [[Category:Skin cancers]] |
Latest revision as of 11:22, 13 May 2024
Page editor | Section editor | ||
---|---|---|---|
Ryan Nguyen, DO University of Illinois at Chicago Chicago, IL, USA |
Elizabeth Buchbinder, MD Dana-Farber Cancer Institute Boston, MA, USA |
Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Melanoma: Cutaneous.
Advanced or metastatic disease, TKI-naive
Imatinib monotherapy
Regimen variant #1, pre-planned escalation
Study | Dates of enrollment | Evidence |
---|---|---|
Hodi et al. 2013 (BUS255) | 2006-2011 | Phase 2 |
Note: upon progression, the dose of imatinib was escalated; see below.
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification and mutation
- Acceptable methods of measurement: PCR or HPLC
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Carvajal et al. 2011 (MSKCC 07-014) | 2007-2010 | Phase 2 |
Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification or mutation
References
- MSKCC 07-014: Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. link to original article contains dosing details in abstract link to PMC article PubMed NCT00470470
Advanced or metastatic disease, TKI-exposed
Imatinib monotherapy
Regimen variant #1, pre-planned escalation
Study | Dates of enrollment | Evidence |
---|---|---|
Hodi et al. 2013 (BUS255) | 2006-2011 | Phase 2 |
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification and mutation
- Acceptable methods of measurement: PCR or HPLC
Prior treatment criteria
- Imatinib 400 mg/day, with progression
References
- BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00424515